Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06708572
NA
Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia
Sponsor: National Liver Institute, Egypt
View on ClinicalTrials.gov
Summary
The aim of the study is to evaluate the use of Granulocyte Colony Stimulating Factor (GCSF) on the clinical and biochemical outcome of type 3 biliary atresia post kasai.
Key Details
Gender
All
Age Range
20 Days - 1 Year
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-12
Completion Date
2026-10-30
Last Updated
2024-12-11
Healthy Volunteers
Yes
Interventions
DRUG
Granulocyte Colony-Stimulating Factor
20 patients will receive subcutaneous GCSF at a daily dose of 10ug/kg for 3 consecutive days. It is administered within 3-4 days after the Kasai procedure.
Locations (1)
National Liver Institute
Cairo, Menofia Governorate, Egypt